- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01555710
Undersøgelse af Palifosfamid-tris i kombination med carboplatin og etoposid i kemoterapi-naive patienter med småcellet lungekræft i omfattende stadier (MATISSE-undersøgelsen)
En multicenter, open-label, adaptiv, randomiseret undersøgelse af Palifosfamide-tris, en ny DNA-krydsbinder, i kombination med carboplatin og etoposid (PaCE) kemoterapi versus carboplatin og etoposid (CE) alene i kemoterapi-naive patienter med små, omfattende stadier Celle lungekræft. MATISSE-undersøgelsen
This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of palifosfamide-tris, carboplatin and etoposide (PaCE) chemotherapy in chemotherapy-naive subjects with extensive-stage small cell lung cancer (SCLC). Eligible subjects will be stratified according to age, gender, and Eastern Cooperative Oncology Group (ECOG) performance status, and randomized in a 1:1 ratio to receive either PaCE or carboplatin and etoposide (CE) chemotherapy.
The study design uses an adaptive group sequential approach with sample size re-estimation at the interim analysis.
Secondary efficacy endpoints include objective response rate (ORR), progression-free survival (PFS), duration of response and changes in quality of life (QOL) and disease-related symptoms. Tumor-related endpoints will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.
The safety of study treatments will be assessed by the frequency and severity of adverse events as determined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03. To provide an initial confirmation of safety, an early interim analysis of safety data only will be performed.
An independent Data Monitoring Committee (DMC) will be convened to assess the safety and efficacy of the study interventions and to monitor the overall conduct of the clinical trial.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Wollongong, New South Wales, Australien, 2500
- Southern Medical Day Oncology Care Centre
-
-
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 4G5
- Hôpital Laval
-
-
-
-
England
-
Manchester, England, Det Forenede Kongerige, M23 9LT
- Wythenshawe Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35205
- Birmingham Hematology and Oncology Associates, LLC
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- University of Southern California
-
Santa Rosa, California, Forenede Stater, 95403
- Redwood Regional Oncology Group
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19713
- Christiana Care Health Services
-
-
Florida
-
Jacksonville, Florida, Forenede Stater, 32207
- Baptist Cancer Institute
-
Port Saint Lucie, Florida, Forenede Stater, 34952
- Hematology Oncology Associates of the Treasure Coast
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30318
- Peachtree Hematology Oncology Consultants
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush University Medical Center
-
Galesburg, Illinois, Forenede Stater, 61401
- Medical and Surgical Specialists, LLC
-
Niles, Illinois, Forenede Stater, 60714-5905
- Illinois Cancer Specialists
-
-
Indiana
-
Fishers, Indiana, Forenede Stater, 46037
- Central Indiana Cancer Centers
-
Goshen, Indiana, Forenede Stater, 46526
- Goshen Center for Cancer Care
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University
-
Lafayette, Indiana, Forenede Stater, 47905
- Horizon Oncology Center
-
Muncie, Indiana, Forenede Stater, 47303
- Indiana University Health Ball Memorial Hospital
-
-
Kansas
-
Overland Park, Kansas, Forenede Stater, 66210
- University of Kansas Hospital
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40503
- Central Baptist Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70809
- Medical Oncology, LLC
-
-
Maryland
-
Frederick, Maryland, Forenede Stater, 21701
- Frederick Memorial Hospital Regional Cancer Therapy Center
-
-
Michigan
-
Wyoming, Michigan, Forenede Stater, 49519
- Metro Health Cancer Center
-
-
Minnesota
-
Duluth, Minnesota, Forenede Stater, 55805
- Saint Mary's Medical Center
-
Minneapolis, Minnesota, Forenede Stater, 55407
- Virginia Piper Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- John Theurer Cancer Center at Hackensack University Medical Center
-
Morristown, New Jersey, Forenede Stater, 07962
- Hematology Oncology Associates of Northern New Jersey, PA, Carol G. Simon Cancer Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Forenede Stater, 12110-2188
- New York Oncology Hematology, PC
-
The Bronx, New York, Forenede Stater, 10461
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- The Christ Hospital
-
Dayton, Ohio, Forenede Stater, 45429
- Dayton Cancer Center, Medical Oncology Hematology Associates
-
-
Pennsylvania
-
Kingston, Pennsylvania, Forenede Stater, 18704
- Medical Oncology Associates Of Wyoming Valley, PC
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29403
- Charleston Hematology Oncology Associates, PA
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75230-6899
- Texas Oncology-Medical City Dallas
-
Dallas, Texas, Forenede Stater, 75246
- Texas Oncology- Baylor, Charles A. Sammons Cancer Center
-
Galveston, Texas, Forenede Stater, 77555-0565
- University of Texas Medical Branch at Galveston
-
Houston, Texas, Forenede Stater, 77024
- Oncology Consultants, PA
-
Wichita Falls, Texas, Forenede Stater, 76310-1610
- Texas Oncology, PA
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05405
- Fletcher Allen Health Care
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Fairfax Northern Virginia Hematology-Oncology, PC
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Swedish Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53705
- Wisconsin Institutes for Medical Research
-
-
-
-
-
Strasbourg, Frankrig, 67085
- Centre Paul Strauss
-
-
Auvergne-Rhône-Alpes
-
Pierre Bénité, Auvergne-Rhône-Alpes, Frankrig, 69495
- Centre Hospitalier Lyon Sud
-
-
Basse-normandie
-
Caen, Basse-normandie, Frankrig, 14076
- Centre François Baclesse
-
-
Brittany Region
-
Brest, Brittany Region, Frankrig, 29200
- Centre Hospitalier Universitaire -Hôpital Morvan
-
-
Centre-Val de Loire
-
Tours, Centre-Val de Loire, Frankrig, 97044
- Centre Hospitalier Universitaire, Hopital Bretonneau
-
-
Limousin, Lorraine
-
Limoges, Limousin, Lorraine, Frankrig, 87042
- Hôpital du Cluzeau
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, Frankrig, 44805
- Institut de Cancérologie de l'Ouest - René Gauducheau
-
-
Provence-Alpes-Côte d'Azur Region
-
Marseille, Provence-Alpes-Côte d'Azur Region, Frankrig, 13008
- Hôpital Saint Joseph
-
-
-
-
-
Haifa, Israel
- Rambam Medical Center
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization, Ein Kerem
-
Kfar Saba, Israel
- Meir Hospital Sapir Medical Center
-
Nahariya, Israel, 22100
- Western Gallilee Medical Center
-
Petah Tikva, Israel, 49100
- Rabin Medical Center Beilinson Campus
-
-
-
-
-
Genova, Italien
- Istituto Nazionale per la Ricerca sul Cancro
-
Milan, Italien, 20162
- Azienda Ospedaliera Ospedale Niguarda Ca' Granda
-
Trento, Italien, 38100
- Presidio Ospedaliero S. Chiara
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen
- Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie w Warszawie
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polen
- Uniwersyteckie Centrum Kliniczne
-
Gdansk, Pomeranian Voivodeship, Polen
- Wojewódzkie Centrum Onkologii
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polen
- Specjalistyczny Szpital im. Alfreda Sokolowskiego
-
-
-
-
-
Chelaybinsk, Rusland, 454087
- State Budget Institution of Healthcare "Chelyabinsk Regional Clinical Oncology Dispensary"
-
Ivanovo, Rusland
- Ivanovo Regional Oncology Centre
-
Moscow, Rusland
- Cancer Research Center n.a. N.N. Blokhin
-
Nizhny Novgorod, Rusland, 603081
- GUZ of Nizhegorodskiy region, Nizhnij Novgorod City Oncology Dispensary
-
Saint Petersburg, Rusland, 194044
- State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
-
Saint Petersburg, Rusland
- Saint-Petersburg State Medical University n. a. I. P. Pavlov
-
Yaroslavl, Rusland, 150040
- State healthcare institution of Yaroslavl region "Regional Clinical Oncologic Hospital"
-
-
Bashkortostan Republic
-
Ufa, Bashkortostan Republic, Rusland, 450054
- Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
-
-
Moscow
-
Moscow Region, Moscow, Rusland, 143423
- City Oncology Hospital # 62
-
-
Primorskiy (Maritime) Kray
-
Arkhangelsk, Primorskiy (Maritime) Kray, Rusland, 163045
- State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
-
-
Tatarstan Republic
-
Kazan', Tatarstan Republic, Rusland
- Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
-
-
-
-
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
-
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Ungarn
- Debreceni Egyetem Orvos és Egészségtudományi Centrum
-
-
Heves County
-
Mátraháza, Heves County, Ungarn
- Mátrai Gyógyintézet
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Documented extensive-stage small cell lung cancer.
- Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests.
- Male and female patients must agree to use a highly reliable method of birth control during study participation.
- Able to provide informed consent
Exclusion Criteria:
- Previously untreated (non-irradiated), symptomatic brain metastases.
- Known allergy to any of the study drugs or their excipients.
- Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).
- Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consultation with the medical monitor provided the patient's prognosis is best defined by the extensive-stage small cell lung cancer).
- Currently pregnant or nursing.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Palifosfamide-tris plus Carboplatin and Etoposide
Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles. |
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles. |
|
Aktiv komparator: Carboplatin plus Etoposide
Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. |
AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles. AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Samlet overlevelse (OS)
Tidsramme: Vurderet hver 12. uge for overlevelse indtil 1 år efter afslutning af tilmelding
|
Vurderet hver 12. uge for overlevelse indtil 1 år efter afslutning af tilmelding
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Progressionsfri overlevelse (PFS)
Tidsramme: Vurderet hver 6. uge i 22 uger, derefter hver 12. uge indtil fremadskridende sygdom, påbegyndelse af alternativ kræftbehandling eller 1 år efter den sidst indrullerede patient (alt efter hvad der er hurtigst)
|
Vurderet hver 6. uge i 22 uger, derefter hver 12. uge indtil fremadskridende sygdom, påbegyndelse af alternativ kræftbehandling eller 1 år efter den sidst indrullerede patient (alt efter hvad der er hurtigst)
|
|
Objektiv responsrate (ORR)
Tidsramme: Vurderet hver 6. uge i 22 uger, derefter hver 12. uge, indtil et delvist eller fuldstændigt svar er bekræftet
|
Vurderet hver 6. uge i 22 uger, derefter hver 12. uge, indtil et delvist eller fuldstændigt svar er bekræftet
|
|
Svarvarighed
Tidsramme: Tid fra datoen for første objektive respons (delvis eller fuldstændig respons), med efterfølgende bekræftelse, indtil datoen for sygdomsprogression eller forekomsten af dødsfald
|
Tid fra datoen for første objektive respons (delvis eller fuldstændig respons), med efterfølgende bekræftelse, indtil datoen for sygdomsprogression eller forekomsten af dødsfald
|
|
Quality of Life (QOL) as Assessed by the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Module (QLQ-LC13)
Tidsramme: Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
|
Assessed every 3 weeks for 22 weeks, then every 12 weeks until 1 year following the last patient enrolled
|
|
Safety Parameters (Adverse Events and Number of Findings: Physical Examinations, Electrocardiograms [ECGs], Vital Signs, and Clinical Laboratory Results) Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 4.03
Tidsramme: 22 weeks
|
22 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Lungesygdomme
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Småcellet lungekarcinom
- Organiske kemikalier
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glukosider
- Glycosider
- Koordinationskomplekser
- Etoposid
- Carboplatin
- Isophosphamid sennep
Andre undersøgelses-id-numre
- IPM3002
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .